DIAN-TU Funding and Study Team

The DIAN-TU acknowledges the many individuals who have contributed to the DIAN-TU Trials including funding partners, leadership team, core leaders, project arm leaders, study sites and institutional study partners listed in the following pages. *All manuscripts should include one of the following statements of acknowledgement of the DIAN-TU Team located at DIAN.wustl.edu.*

**Acknowledgement Statements**

**General DIAN-TU and/or DIAN-TU Trial Platform (not drug specific or all drugs):**

The DIAN-TU is supported by the Alzheimer’s Association, GHR Foundation, an anonymous organization, and the DIAN-TU Pharma Consortium (https://dian.wustl.edu/our-research/the-pharma-consortium/).

The DIAN-TU-001 Trial has received support from the Alzheimer’s Association, Eli Lilly and Company, Roche, Janssen Pharmaceuticals, NIH U01AG042791, NIH U01AG042791-S1 (FNIH and Accelerating Medicines Partnership), NIH R1AG046179, NIH R01/R56 AG053267, NIH R01AG53267-S1, NIH R01AG53267-S2, Avid Radiopharmaceuticals, GHR Foundation, and an anonymous organization. In-kind support has been received from CogState and Bracket. We acknowledge the altruism of the participants and their families and contributions of the DIAN and DIAN-TU research and support staff at each of the participating sites (https://dian.wustl.edu/wp-content/uploads/2019/04/DIAN-TU-Publications_Acknowledgement_V30.pdf) for their contributions to this study.

**DIAN-TU Trial Platform - Sola/Gant specific:**

The DIAN-TU is supported by the Alzheimer’s Association, GHR Foundation, an anonymous organization, and the DIAN-TU Pharma Consortium (https://dian.wustl.edu/our-research/the-pharma-consortium/).

This research for the DIAN-TU-001 Trial has received support from the Alzheimer’s Association, Eli Lilly and Company, Roche, NIH U01AG042791, NIH U01AG042791-S1 (FNIH and Accelerating Medicines Partnership), NIH R1AG046179, NIH R01AG53267-S1, Avid Radiopharmaceuticals, GHR Foundation, and an anonymous organization. In-kind support has been received from CogState and Bracket. We acknowledge the altruism of the participants and their families and contributions of the DIAN and DIAN-TU research and support staff at each of the participating sites (https://dian.wustl.edu/wp-content/uploads/2019/04/DIAN-TU-Publications_Acknowledgement_V30.pdf) for their contributions to this study.

**DIAN-TU Trial Platform – Atabecestat specific:**

The DIAN-TU is supported by the Alzheimer’s Association, GHR Foundation, an anonymous organization, and the DIAN-TU Pharma Consortium (https://dian.wustl.edu/our-research/the-pharma-consortium/).

This research for the DIAN-TU-001 Trial has received support from the Alzheimer’s Association, Janssen Pharmaceuticals, NIH R01/R56 AG053267, NIH R01AG53267-S1, GHR Foundation, and an anonymous organization. We acknowledge the altruism of the participants and their families and contributions of the DIAN and DIAN-TU research and support staff at each of the participating sites (https://dian.wustl.edu/wp-content/uploads/2019/04/DIAN-TU-Publications_Acknowledgement_V30.pdf) for their contributions to this study.
Authorship and Acknowledgements: The overarching considerations for DIAN-TU publications are collaboration and inclusiveness. When studies use DIAN-TU Trial data and/or biospecimens processed by the DIAN-TU Coordinating Center Cores, an invitation to collaborate (meriting authorship) on the manuscript should be issued to respective DIAN-TU Study Team Members as defined below:

**DIAN-TU Study Team Members (see complete list of individuals on pages 3-20)**

**Invite to co-author:**
- Leadership Team
- Pharma Partners
- Core Leaders (Core leaders may include staff member, fellow, co-investigator)
- Site Principal Investigators

**Acknowledge DIAN-TU Study Team:**
- DIAN-TU Staff
- Pharma Teams
- Commercial Vendors and Collaborators
- DSMB Members
- Therapy Evaluation Committee
- Clinical Trials Committee
- Data Sharing and Communications Committee
- DIAN EXR Referring Clinicians and Researchers
- DIAN-TU Collaborators and Advisors
- Commercial Vendors and Collaborators
- Acknowledge Funding Partners
Funding Partners
Through public/private support and partnership, the DIAN-TU has launched trials to provide advancement of treatments, scientific understanding and improvements in the approach to Alzheimer’s disease drug developments.

- DIAN-TU Trial Pharma Partners: Lilly (Solanazemab), Roche (Gantenerumab) and Janssen (BACEi)
- Alzheimer’s Association
- GHR Foundation
- National Institute on Aging of the National Institutes of Health; Accelerating Medicines Partnership (AMP) - U01 AG042791, R01 AG046179, R01/R56 AG053267, R13 AG055232
- DIAN-TU Pharma Consortium: Biogen Idec, Eisai, Janssen, Lilly, Roche/Genentech, United Neuroscience (Former Members: Abbvie, Amgen, AstraZeneca, Elan, Forum, Mithridion, Novartis Pharm AG, Pfizer, Sanofi-Aventis)
- CogState
- Bracket
- Avid Radiopharmaceuticals
- Anonymous Foundation

EXAMPLE: The DIAN-TU is supported by the Alzheimer’s Association, GHR Foundation, an anonymous organization and the DIAN-TU Pharma Consortium (Active: Eli Lilly and Company/Avid Radiopharmaceuticals, Hoffman-La Roche/Genentech, Biogen, Eisai, Janssen, and United Neuroscience. Previous: Abbvie, Amgen, AstraZeneca, Forum, Mithridion, Novartis, Pfizer, Sanofi). The DIAN-TU-001 Clinical Trial is supported by Pharmaceutical Partners Eli Lilly and Company, Hoffman-La Roche and Janssen, the Alzheimer’s Association, NIH U01AG042791, NIH U01AG42791-S1 (FNIH and Accelerating Medicines Partnership), NIH R01AG046179, NIH R56AG053267, NIH R01AG053267, NIH R01AG053267-S1, NIH R01AG053267-S2, NIH U01AG059798, Avid Radiopharmaceuticals, GHR Foundation, and an anonymous organization. In-kind support has been received from CogState and Bracket.

Leadership Team

Washington University School of Medicine, Department of Neurology

Randall Bateman, MD
Director and Principal Investigator DIAN-TU
Eric McDade, DO
Associate Director, DIAN-TU

David Clifford, MD
Associate Director, Medical Director, DIAN-TU

Project Arm Leaders

Steve Salloway, MD, Gantenerumab
Butler Hospital

Martin Farlow, MD, Solanazemab
Indiana University

Lon Schneider, MD, BACE
University of Southern California

Pharma Partners

Eli Lilly
John Sims
Cheryl Brown
Eric Siemers (retired)

Hoffman La-Roche
Greg Klein
Smilijana Ristic
Monika Baudler

Janssen
Gary Romano
Hong Sun
Luc Tritsman (retired)
DIAN-TU Core Leaders

Randall Bateman, MD  
Administrative Core Leader  
Washington University School of Medicine

Anne Fagan, PhD  
Biomarker Core Leader  
Washington University School of Medicine

Chengjie Xiong, PhD  
Biostatistics Core Leader  
Washington University School of Medicine

Guoqiao Wang, PhD  
Biostatistics Co-Core Leader  
Washington University School of Medicine

Jason Hassenstab, PhD  
Cognition Core Leader  
Washington University School of Medicine

Alison Goate, DPhil  
Genetics Core Leader  
Mt. Sinai School of Medicine

Carlos Cruchaga, PhD  
Genetics Core Leader  
Washington University School of Medicine

Tammie Benzinger, MD  
Imaging Core Leader  
Washington University School of Medicine

Rick Perrin, MD  
Neuropathology Core Leader  
Washington University School of Medicine

Cliff Jack, MD  
MRI, Mayo Clinic

Robert Koepp, MD  
PET Imaging, University of Michigan

Nigel Cairns, MD (retired)  
Neuropathology Core Leader  
Washington University School of Medicine

Peter Snyder, PhD  
(Former Cognition Core Leader)  
Brown University
DIAN-TU Staff

Administration
Amanda Fulbright, Grant Specialist
Jacki Mallmann, Senior Grant Specialist
Karen McCann, Financial Accounting Assistant
Julie Murphy, Accounting/Purchasing Assistant
Anna Santacruz, Administrative Director
Jeanette Schillizzi – Research Administrator
Shannon Sweeney, Finance Analyst

Biomarker
Kelley Coalier, Lead Scientist
Fatima Amtashar, QC Technician
Sushila Sathyan, Archivist

Clinical Operations
Susan Mills – Director of Clinical Operations
Nicole Kelley - Associate Director of Clinical Operations
Stephanie Belyew - Clinical Research Development Coordinator, Site, Vendor and GCP Management
Angela Fuqua - Clinical Research Development Coordinator, Clinical Scale, Drug Supply and Vendor Management
Annette Stiebel - Clinical Research Development Coordinator
Caryll Bentley - Contract Project Manager
JaNeen Wisner - Contract Project Coordinator
Tayona Mayhew - Data Management Specialist
Zenobia Bridgewater - Clinical Research Coordinator
Molly Fitzgerald - Clinical Research Study Assistant I
Erica Fowler - Clinical Research Coordinator I
Kurtis Hanks - Clinical Research Coordinator I
Dottie Heller - Research Nurse Coordinator II
Latoya Jones - Clinical Research Coordinator II
Paulette MacDougall - Research Nurse Coordinator II
Michelle Jorke - Clinical Research Coordinator II
Eugene Rubin - QC
Jessi Smith - Senior Clinical Research Coordinator
Mary Wolfsberger - Clinical Research Coordinator

DIAN Expanded Registry (DIAN EXR)
Eric McDade - Director
Randall Bateman – Associate Director
Jorge Llibre-Guerra – Post-Doctoral Associate
Ellen Ziegemeier - Senior Clinical Research Coordinator
Jennifer Petranek - Clinical Coordinator I
Sarah Adams - Clinical Research Coordinator II
Susan Brandon - Clinical Research Coordinator II

DIAN-TU Post-Doctoral Associate(s)
Jorge Llibre-Guerra – Post-Doctoral Associate

Imaging
Theresa Butler - Research Lab Manager
Lisa Cash - Senior Clinical Research Coordinator
Jon Christensen - Staff Scientist
Aylin Dincer - Research Assistant
Tony Durbin - Senior Clinical Research Coordinator
Shaney Flores - Research Assistant
Karl Friedrichsen - Research Assistant
Brian Gordon - Co-Investigator
Russ Hornbeck - Project Manager
Nelly Joseph-Mathurin - Post-doc
Sarah Keefe - Research Assistant
Lakisha Lloyd - Research Coordinator
Laura Marple - Research Technician II
Austin McCullough - Graduate Research Assistant
Jeanine Portell - Senior Clinical Research Coordinator
Stephanie Schultz - Pre-Doctoral Trainee
Sally Schwarz - Co-Investigator
Yi Su - Co-Investigator
Andrei Vlassenko - Co-Investigator
Qing Wang - Post-doc
Jinbin Xu - Co-Investigator

Neuropathology
Erin Franklin - Research Coordinator

Biostatistics
Yan Li - Co-Investigator
Xu Xiong - Database Manager

Cognition
Andy Aschenbrenner – Assistant Professor
Jennifer Smith - Professional Rater III
Marisol Tahan, Clinical Research Coordinator
Eli Lilly Team
Isabella Velona, Clinical Trial Project Manager
Scott Andersen, Biostatistician
Michele Mancini, GPS
Brian Willis, PK/PD Project Leader
Sonia Nijampatnam, Pharmaceutical Project Management
Kathryn Broderick, Global Regulatory Affairs
Julie Bush, Product Delivery
Shamrock Garrett, Sr. CTMA
Traci Peddie, Data Sciences & Solutions
Natalie Vantwoud, Data Management
Barbara Lightfoot-Owens, Medical Writer
John Brad-Holmes, Central Lab

Former
Phyllis Ferrell Barkman
Russ Barton
Lauren Brunke
Robert Dean
Deanilee Deckard
Ann Catherine Downing
Ganapathy Goppalrathnam
David Henley
Janice Hitchcock
Tracie Peddie
Melissa Pugh
Tami Jo Rayle
Shiloh Scott
James Senetar
Gopalan Sethuraman
Eric Siemers
Brian Steuenwald
Connie Tong
Jim Vandergriff

Avid
Michael Devous
Erica Elephant
Laura Harper
Marybeth Howlett
Mark Mintun
Michael Pontecorvo
Hoffman-LaRoche Team
Monika Baudler, LifeCycle Leader
Rachelle Doody, Global Head of Neurodegeneration
Paul Delmar, Principal Statistical Scientist
Carsten Hofmann, Clinical Pharmacologist
Michaela Jahn, Global Biometrics Team Leader
Geoff Kerchner, Global Development Leader
Gregory Klein, Biomarker Experimental Medicine Leader
Smiljana Ristic, Associate Group Medical Director
Alison Searle, Operations Program Leader
Marco Sonderegger, Technical Development Leader
Roz Sutton, EU Regulatory Partner
Janette Turner, US Regulatory Partner
Jaku Wojtowicz, Safety Science Director
Susan Yule, Global Regulatory Leader

Former
Elizabeth Ashford, Operations Program Leader
Bogdon Balas, Safety Science Leader
Estelle Vester-Blokland, LifeCycle Leader
Stephanie Capo-Chichi, EU Regulatory Partner
David Agnew, Global Study Manager
Ernest Dorflinger, Translational Medicine Leader
Efe Egharevba, Global Study Manager
Christelle Laroche, Technical Development Leader
Isabelle Bauer Dauphin, Technical Development Leader
Rob Lasser, Global Development Leader
Ferenc Martenyi, Global Development Leader
Glenn Morrison, Global Development Leader
Tania Nikolcheva, Biomarker Experimental Medicine Leader
Michael Rabbia, Statistical Scientist
Juha Savola, Project Leader
Janice Smith, Clinical Science Leader
Dietmar Volz, Statistical Scientist
Janssen Team
Caitlin Beatty
Jennifer Bogert
Miranda Damen
Carol Davies
Marisa Ehinger
Suzanne Foy
Monique Franc
Betty Guinter
Katrin Haeverans
Megan Katz
Hartmuth Kolb
Cathy Marseca
Reena Mistry
Sophie Morin
Gary Romano
Maria Schpatschynskyj
Hong Sun
Monika Sulidis
Luc Tritsman
The following should be acknowledged in DIAN-TU Publications

- Commercial Vendors and Collaborators
- DSMB Members
- Therapy Evaluation Committee
- Clinical Trials Committee
- Data Sharing and Communications Committee
- DIAN EXR Referring Clinicians and Researchers
- DIAN-TU Advisers and Collaborators

DIAN-TU Commercial Vendors and Collaborators

- IQVIA
- Berry Consultants
- CogState
- Granzer Regulatory Consulting
- Cardinal Health Regulatory Sciences
- Signat

DIAN-TU DSMB Members

The DSMB is an expert advisory group who functions as a review committee independent from the Sponsor. DSMB members meet without the Sponsor or study team members to review and discuss provided data. The DSMB scope is to review study data to ensure the safety of subjects enrolled in DIAN-TU-001.

Gary Cutter, DSMB Chairperson
Steve Greenberg
Scott Kim
David Knopman
Willis Maddrey (Retired)
Kristine Yaffe
Karl Kieburtz (Retired DSMB Chairperson)
Allan Levey (Retired)

DIAN-TU Data Sharing and Communications Committee

Andy Aschenbrenner, PhD, Committee Chair
Anna Santacruz, Administrative Director
DIAN-TU Therapy Evaluation Committee
The DIAN-TU established a Therapy Evaluation Committee comprised of worldwide experts in AD research and clinical studies from multiple institutions to vet and evaluate compounds nominated for participation in the DIAN-TU trial. Areas of expertise include clinical trials in AD and other diseases, autosomal dominant and sporadic AD, immunotherapy, neurodegenerative disorders, cell and molecular biology of AD, preclinical AD studies, proteomics (AD related proteins), AD neuropathology, cognitive and clinical testing, cerebral amyloid angiopathy, neuroimaging, translational AD trials, and tau biology.

Randall Bateman, MD, Chair, Washington University
Eric McDade, DO, Co-Chair, Washington University
Paul Aisen, MD, Alzheimer’s Therapeutic Research Institute (clinical trials)
Jasmeer Chhatwal, MD, PhD, MMSc, Massachusetts General Hospital, Harvard Medical School (imaging)
David Clifford, MD, Washington University School of Medicine (Medical Director, DIAN-TU Trials)
David Cribbs, MD, UC Irvine (immunotherapy)
Nick Fox, MD, FRCP, FMedSci, Dementia Research Centre (genetics)
Serge Gauthier, Serge Gauthier, CM, MD, FRCPC, Director, AD & Related Disorders Unit
McGill Centre for Studies in Aging (clinical trials)
David Holtzman, MD, Washington University School of Medicine (neurodegeneration, animal models)
Matthias Jucker, PhD, Hertie Institute for Clinical Brain Research (translational AD)
Jeff Kelly, MD, Scripps (proteomics)
Virginia Lee, PhD, University of Pennsylvania, Perelman School of Medicine (tau biology)
Simon Mead, FRCP, PhD, Institute of Prion Diseases (genetics)
Cath Mummery, PhD, FRCP, Dementia Research Centre (genetics)
Erik Musiek, MD, PhD, Washington University School of Medicine (translational AD)
Erik Roberson, MD, PhD, University of Alabama (tau proteins)
Mathias Staufenbiel, PhD, Hertie Institute for Clinical Brain Research, Tubingen (pre-clinical and clinical AD studies)
Robert Vassar, PhD, Northwestern (cell and molecular biology)

Former TEC Members
Bart DeStrooper, PhD, VIB, K.U. Leuven, Germany
William Klunk, MD, PhD, University of Pittsburgh, Pennsylvania
Cynthia Lemere, MD, Brigham and Women’s Hospital, Boston, Massachusetts
John C. Morris, MD, Washington University School of Medicine, St. Louis, Missouri
Clinical Trials Committee (CTC) Members

Randall Bateman, Washington University in St. Louis School of Medicine
John Morris, Washington University in St. Louis School of Medicine
Chengjie Xiong, Washington University in St. Louis School of Medicine
Denise Heinrichs, DIAN Family Representative
John Ringman, University of California, Los Angeles
Laurie Ryan, Division of Science, National Institute on Aging
Neil Buckholtz, National Institute on Aging
Reisa Sperling, Director, Center for Alzheimer Research and Treatment
Stephen Salloway, Butler Hospital
Paul Aisen, University of California, San Diego
Anna Santacruz, Washington University in St. Louis School of Medicine
Gabrielle Strobel, Alzheimer Research Forum
Bill Klunk, University of Pittsburgh
William Thies, Alzheimer’s Association

CTC Steering Committee Members

Anne Fagan, Washington University in St. Louis School of Medicine
Mark Mintun, Washington University in St. Louis School of Medicine
Natalie Ryan, University College London
Virginia Buckles, Washington University in St. Louis School of Medicine
David Hawver, FDA
Martin Farlow, Indiana University
Maritza Ciliberto, DIAN Family Representative
Ralph Martins, Edith Cowan University
Jennifer Williamson, Columbia University
## Study Sites

### Argentina

**Instituto de Investigaciones Neurologicas Fleni**  

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ricardo F. Allegri</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Patricio Chrem Mendez</td>
<td>Co-Investigator</td>
</tr>
<tr>
<td>Lucia Crivelli</td>
<td>Neuropsychologist</td>
</tr>
<tr>
<td>Ezequiel Surace</td>
<td>Biologist</td>
</tr>
<tr>
<td>Gustavo Sevlever</td>
<td>Neuropathologist</td>
</tr>
<tr>
<td>Silvia Vazquez</td>
<td>Imaging Principal Investigator</td>
</tr>
<tr>
<td>Luciana Armanini</td>
<td>Study Coordinator</td>
</tr>
</tbody>
</table>

### Australia

**Neuroscience Research – Sydney (SG, AV)**

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Brooks</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Michael J Fulham</td>
<td>Imaging Principal Investigator</td>
</tr>
<tr>
<td>Jacob Bechara</td>
<td>Study Coordinator</td>
</tr>
<tr>
<td>David Foxe</td>
<td>CDR assessments</td>
</tr>
</tbody>
</table>

**Australian Alzheimer’s Research Foundation – Perth (SG)**

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roger Clarnette</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Nick Reynders</td>
<td>Imaging Principal Investigator</td>
</tr>
<tr>
<td>Paula Mather</td>
<td>Study Coordinator</td>
</tr>
</tbody>
</table>

**University of Melbourne – Melbourne (SG, AV)**

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin Masters</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Christopher Rowe</td>
<td>Imaging Principal Investigator</td>
</tr>
<tr>
<td>Bev Clinch</td>
<td>Study Coordinator</td>
</tr>
<tr>
<td>David Baxendale</td>
<td>Back up Coordinator</td>
</tr>
</tbody>
</table>

### Brazil

**University of São Paulo**

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ricardo Nitrini</td>
<td>Principal Investigator</td>
</tr>
</tbody>
</table>

---

**Legend for site participation:**

SG = Solanazemab and Gantenerumab arms;  
B = BACE;  
MK = MK6240 Tau;  
AV = AV1451 Tau;  
CRI = Cognitive Run-in
## Study Sites (continued)

### Canada

<table>
<thead>
<tr>
<th>Study Site</th>
<th>Principal Investigator</th>
<th>Imaging Co-Investigator</th>
<th>Study Coordinator</th>
<th>Back up Coordinator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Douglas Hospital Research Centre (SG, AV)</td>
<td>Serge Gauthier</td>
<td>Pedro Rosa-Neto</td>
<td>Carley Mayhew</td>
<td>Laura Robb</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vancouver Coastal Health Authority (SG, AV)</td>
<td>Robin Hsiung</td>
<td>Dan Worsley</td>
<td>Michele Assaly</td>
<td>Eloise Nicklin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunnybrook Health Science Centre (SG, AV)</td>
<td>Mario Masellis</td>
<td>Katie Sharp</td>
<td>Stephanie Hetherington</td>
<td>Eloise Nicklin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Universite Laval</td>
<td>Robert Laforce</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Colombia

<table>
<thead>
<tr>
<th>Study Site</th>
<th>Principal Investigator</th>
<th>Sub-Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grupo de Neurociencias Sede de la Universidad de Antioquia</td>
<td>Francisco Lopera</td>
<td>Yakeel Quiroz</td>
</tr>
</tbody>
</table>

**Legend for site participation:**
- SG = Solanazemab and Gantenerumab arms
- B = BACE
- MK = MK6240 Tau
- AV = AV1451 Tau
- CRI = Cognitive Run-in
### Study Sites (continued)

#### France

**CHU de Rouen (SG, AV)**
www.alzheimer-genetique.fr

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Wallon, MD, PhD</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Didier Hannequin, MD, PhD</td>
<td>Sub-investigator</td>
</tr>
<tr>
<td>Alexandre Morin, MD</td>
<td>Sub-Investigator</td>
</tr>
<tr>
<td>Aline Zarea, MD</td>
<td>Sub-investigator</td>
</tr>
<tr>
<td>Emmanuel Gerardin, MD, PhD</td>
<td>MRI Neuroimaging Investigator</td>
</tr>
<tr>
<td>Pierre Bohn, PharmaD</td>
<td>Imaging principal Investigator</td>
</tr>
<tr>
<td>Mathieu Chastan, MD</td>
<td>Imaging Sub-Investigator</td>
</tr>
<tr>
<td>Pierre Vera, MD, PhD</td>
<td>Imaging Sub-Investigator</td>
</tr>
<tr>
<td>Marion Colnot, PharmaD</td>
<td>Hospital Pharmacist</td>
</tr>
<tr>
<td>Nathalie Donnadieu, PharmaD</td>
<td>Hospital Pharmacist</td>
</tr>
<tr>
<td>Muriel Quillard-Muraine, MD, PhD</td>
<td>Biologist</td>
</tr>
<tr>
<td>Celine Bergot</td>
<td>Study Coordinator</td>
</tr>
<tr>
<td>Severine Jourdain</td>
<td>Back-up Study Coordinator</td>
</tr>
</tbody>
</table>

**Hôpital Larrey – Angers (SG)**

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valérie Chauviré, MD</td>
<td>Sub-investigator</td>
</tr>
<tr>
<td>Frédérique Etcharry-Bouyx, MD</td>
<td>Sub-investigator</td>
</tr>
</tbody>
</table>

**Groupe Hospitalier Pitié (SG, AV)**

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bruno Dubois</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Marie-Odile Habert</td>
<td>Imaging Principal Investigator</td>
</tr>
<tr>
<td>Nadja Younsi</td>
<td>Back up Coordinator</td>
</tr>
</tbody>
</table>

**Hôpital Neurologique Pierre Wertheimer—Lyon (SG)**

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maïté Formaglio</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Didier Lebars</td>
<td>Imaging Principal Investigator</td>
</tr>
<tr>
<td>Najat El Kfif</td>
<td>Study Coordinator</td>
</tr>
<tr>
<td>Aurélie Jullien</td>
<td>Back up Coordinator</td>
</tr>
</tbody>
</table>

**CHU de Toulouse (SG, AV)**

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jereme Pariente</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Pierre Payoux</td>
<td>Imaging Principal Investigator</td>
</tr>
<tr>
<td>Claire Thalamas</td>
<td>CID</td>
</tr>
<tr>
<td>Amel Driff</td>
<td>CRA</td>
</tr>
<tr>
<td>Elsa Pomies</td>
<td>Neuropsychologist</td>
</tr>
<tr>
<td>Pascale Gauteul</td>
<td>Study Coordinator</td>
</tr>
</tbody>
</table>

**Legend for site participation:**

- **SG** = Solanazemab and Gantenerumab arms
- **B** = BACE
- **MK** = MK6240 Tau
- **AV** = AV1451 Tau
- **CRI** = Cognitive Run-in
## Study Sites (continued)

### France (continued)

<table>
<thead>
<tr>
<th>Centre Hospitalier Universitaire - Lille (SG, AV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Florence Pasquier</td>
</tr>
<tr>
<td>Adeline Rollin-Sillaume</td>
</tr>
<tr>
<td>Franck Semah</td>
</tr>
<tr>
<td>Laetitia Breuilh</td>
</tr>
<tr>
<td>Manon Laforce</td>
</tr>
<tr>
<td>Michael Bottlaender, MD, PhD</td>
</tr>
</tbody>
</table>

**Orsay Imaging**

| Michael Bottlaender, MD, PhD | Imaging Principal Investigator |

### Germany

**German Center for Neurodegenerative Diseases (DZNE), Universitaetsklinikum Tuebingen**

| Christoph Laske | Principal Investigator |

<table>
<thead>
<tr>
<th>Ludwig-Maximilians-Universität</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johannes Levin</td>
</tr>
<tr>
<td>Adrian Danek</td>
</tr>
<tr>
<td>Jonathan Vöglein</td>
</tr>
<tr>
<td>Igor Yakushev</td>
</tr>
<tr>
<td>Siri Houeland di Bari</td>
</tr>
</tbody>
</table>

### Ireland

**St. Vincent’s University Hospital**

<table>
<thead>
<tr>
<th>Justin Kinsella</th>
<th>Principal Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gillian O'Boyle</td>
<td>Study Coordinator</td>
</tr>
</tbody>
</table>

### Italy

**Azienda Ospedaliera Universitaria Careggi**

| Sandro Sorbi | Principal Investigator |

<table>
<thead>
<tr>
<th>IRCCS Centro San Giovanni di Dio Fatebenefratelli</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giovanni Frisoni</td>
</tr>
<tr>
<td>Sara Gipponi</td>
</tr>
<tr>
<td>Michela Rampini</td>
</tr>
<tr>
<td>Anna Mega</td>
</tr>
<tr>
<td>Emilio Di Maria, MD</td>
</tr>
<tr>
<td>Samantha Galluzzi, MD</td>
</tr>
<tr>
<td>Amalia Cecilia Bruni</td>
</tr>
<tr>
<td>Nicoletta Smirne</td>
</tr>
<tr>
<td>Valentina Laganà</td>
</tr>
<tr>
<td>Fabrizio Tagliavini</td>
</tr>
<tr>
<td>Cristina Muscio</td>
</tr>
<tr>
<td>Alessandro Padovani</td>
</tr>
<tr>
<td>Barbara Borroni</td>
</tr>
<tr>
<td>Elio Scarpini</td>
</tr>
<tr>
<td>Gabriella Salvini Porro</td>
</tr>
</tbody>
</table>

**Legend for site participation:**

SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run-in
### Study Sites (continued)

**Mexico**

<table>
<thead>
<tr>
<th>Instituto Nacional de Neurologica y Neurocirugia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ana Luisa Sosa</td>
</tr>
<tr>
<td>Longoria Mariana</td>
</tr>
</tbody>
</table>

**Netherlands**

<table>
<thead>
<tr>
<th>Amsterdam University Medical Centers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phillip Scheltens</td>
</tr>
</tbody>
</table>

**Spain**

<table>
<thead>
<tr>
<th>Hospital Clinic I Provincial de Barcelona (SG, B, AV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raquel Sanchez-Valle</td>
</tr>
<tr>
<td>Mircea Balasa</td>
</tr>
<tr>
<td>Albert Lladó</td>
</tr>
<tr>
<td>Beatriz Bosch</td>
</tr>
<tr>
<td>Nuria Bargalló</td>
</tr>
<tr>
<td>Ignacio Banzo</td>
</tr>
<tr>
<td>Andres Perisinotti</td>
</tr>
</tbody>
</table>

**United Kingdom**

<table>
<thead>
<tr>
<th>University College London Hospital (SG)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catherine Mummery</td>
</tr>
<tr>
<td>Irfan Kayani</td>
</tr>
<tr>
<td>Jane Douglas</td>
</tr>
<tr>
<td>Miguel Grilo</td>
</tr>
</tbody>
</table>

**Legend for site participation:**

- **SG** = Solanazemab and Gantenerumab arms; **B** = BACE; **MK** = MK6240 Tau; **AV** = AV1451 Tau; **CRI** = Cognitive Run-in
## Study Sites (continued)

### United States

<table>
<thead>
<tr>
<th>Washington University, St. Louis, Missouri (SG, B, AV, MK)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barbara J. Snider, MD</td>
</tr>
<tr>
<td>Tammie Benzinger, MD</td>
</tr>
<tr>
<td>Wendy Sigurdson, RN</td>
</tr>
<tr>
<td>Tamara Donahue, RN</td>
</tr>
<tr>
<td>Peggy Kelly, RN</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Emory University, Atlanta, Georgia (SG, B, AV, MK)</th>
</tr>
</thead>
<tbody>
<tr>
<td>James Lah</td>
</tr>
<tr>
<td>Carolyn Meltzer</td>
</tr>
<tr>
<td>Gail Schwartz</td>
</tr>
<tr>
<td>Phyllis Vaughn</td>
</tr>
<tr>
<td>Lydia Piendel</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>University of Pittsburgh, Pennsylvania (SG, B, AV, MK)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah Berman</td>
</tr>
<tr>
<td>James Mountz</td>
</tr>
<tr>
<td>Lori Macedonia</td>
</tr>
<tr>
<td>Snezana Ikonomovic</td>
</tr>
<tr>
<td>Sarah Goldberg, M.S.</td>
</tr>
<tr>
<td>Elise Weamer, MPH</td>
</tr>
<tr>
<td>James Ruskievitch, BS</td>
</tr>
<tr>
<td>Steven Hegedus</td>
</tr>
<tr>
<td>Lee Tarr</td>
</tr>
<tr>
<td>Tom Potter</td>
</tr>
<tr>
<td>Gina Valetti</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>University of Alabama at Birmingham (SG, B, AV, MK)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erik D. Roberson</td>
</tr>
<tr>
<td>David S. Geldmacher</td>
</tr>
<tr>
<td>Marissa Natelson Love</td>
</tr>
<tr>
<td>Amber Watkins</td>
</tr>
<tr>
<td>Loren Ashley</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Indiana University (SG, B, AV, MK)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jared R. Brosch, M.D.</td>
</tr>
<tr>
<td>Brand Mathews, M.D.</td>
</tr>
<tr>
<td>Arlene Kohn</td>
</tr>
<tr>
<td>Nancy McClaskey, RN</td>
</tr>
<tr>
<td>Jill Buck, RN</td>
</tr>
<tr>
<td>James Fletcher</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Butler Hospital, Providence, Rhode Island (SG, B, AV, MK)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gulam Surti</td>
</tr>
<tr>
<td>Richard Noto</td>
</tr>
<tr>
<td>Courtney Bodge</td>
</tr>
<tr>
<td>William Menard</td>
</tr>
</tbody>
</table>

**Legend for site participation:**
- **SG** = Solanazemab and Gantenerumab arms; **B** = BACE; **MK** = MK6240 Tau; **AV** = AV1451 Tau; **CRI** = Cognitive Run-in
### Study Sites (continued)

#### United States

**University of Puerto Rico (SG, B, AV, MK)**
- Ivonne Z. Jimenez Velazquez: Principal Investigator
- Janice Diaz: Study Coordinator
- Karen Aleman: Study Coordinator

**Yale University, New Haven, Connecticut (SG, B, AV, MK)**
- Christopher Van Dyck: Principal Investigator
- Ming-Kai Chen: Imaging Principal Investigator
- Nina Diepenbrock: Study Coordinator
- Adam Mecca, MD, PhD: Sub-Investigator
- Susan Good, APRN: Study Nurse

**University of California, San Diego (SG, B, AV, MK)**
- Doug Galasko: Principal Investigator
- Carl Hoh: Imaging Principal Investigator
- Dan Szpak: Study Coordinator
- Shawnees Peacock: Back up Coordinator

**University of Washington (SG, B, AV, MK)**
- Suman Jayadev: Principal Investigator
- David Lewis: Imaging Principal Investigator
- Yeung Tuttero: Study Coordinator

**Advocate Lutheran General Hospital, Park Ridge, Illinois**
- Darren Gitelman: Principal Investigator
- Victoria Begoun: Study Coordinator
- Evelyn Torres: Back up Coordinator

**AUSC Keck School of Medicine, Los Angeles, California**
- Sonia Pawluczyk: Principal Investigator

**Columbia University, New York City (SG, B, AV, MK)**
- Lawrence Honig: Principal Investigator
- Chaitanya Divgi: Imaging Principal Investigator
- Ruth B. Tejeda: Rater
- Solciris A. Dominguez: Rater
- Katrina Cuasay: Rater
- Evelyn Dominguez-Rivera: Study Coordinator

**Kerwin Research Center, Dallas, Texas**
- Diana Kerwin: Principal Investigator
- Micah Eimberbrink, PhD: Head of Research Operations

---

**Legend for site participation:**
- SG = Solanazemab and Gantenerumab arms; B = BACE; MK = MK6240 Tau; AV = AV1451 Tau; CRI = Cognitive Run-in
DIAN EXR Referring Clinicians and Researchers

Neelum T. Aggarwal, MD, Rush University Medical Center, Chicago IL
Tom Ala, Center for Alzheimer’s Disease and Related Disorders, Southern Illinois University School of Medicine
Thomas Bird, University of Washington
Sandra E. Black, Sunnybrook Health Sciences Centre, University of Toronto
William J. Burke, MD, Banner Alzheimer’s Institute
Cynthia M. Carlsson, MD, MS, University of Wisconsin School of Medicine and Public Health
Andrew Frank M.D. B.Sc.H. F.R.C.P.(C), Bruyere Continuing Care, Ottawa, Ontario, Canada
James E. Galvin, MD, MPH, Charles E. Schmidt College of Medicine, Florida Atlantic University
Alvin C Holm, MD, Bethesda Hospital, St. Paul, MN
John S.K. Kauwe, Brigham Young University
David Knopman MD, Mayo Clinic, Rochester MN
Sarah Kremen, MD, University of California, Los Angeles
Alan J. Lerner, University Hospitals Cleveland Medical Center
Barry S. Oken, MD, PhD, Oregon Health & Science University
Hamid R. Okhravi, Eastern Virginia Medical School
Ronald C. Petersen, Mayo Clinic
Aimee L. Pierce, MD, University of California Irvine
Marsha J. Polk, MED, University of Texas Health Science Center at San Antonio
John M. Ringman, MD, MS, University Southern California
Sanjeev N. Vaishnavi, MD, PhD, University of Pennsylvania
Sandra Weintraub, Northwestern University Feinberg School of Medicine

DIAN-TU Collaborators and Advisers

John Morris, MD, Senior Advisor
David Holtzman, MD, Senior Advisor
Thomas Bird, MD, University of Washington
Dennis Dickinson, MD, Mayo Clinic, Jacksonville, FL
Peter St. George Hyslop, MD, FRS, FRSC, FRCPC, University of Toronto
M. Marsel Mesulam, MD, Cognitive Neurology and Alzheimer’s Disease Center, Northwestern University
Cornelia Kamp, MBA, University of Rochester

ADCS
Ron Thomas, PhD
Paul Aisen, MD